Your browser doesn't support javascript.
loading
Coupling of Homologous Recombination and the Checkpoint by ATR.
Buisson, Rémi; Niraj, Joshi; Rodrigue, Amélie; Ho, Chu Kwen; Kreuzer, Johannes; Foo, Tzeh Keong; Hardy, Emilie J-L; Dellaire, Graham; Haas, Wilhelm; Xia, Bing; Masson, Jean-Yves; Zou, Lee.
Afiliación
  • Buisson R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Niraj J; CHU de Québec Research Center, Oncology Axis, Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Laval University, Québec City, QC G1V 0A6, Canada.
  • Rodrigue A; CHU de Québec Research Center, Oncology Axis, Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Laval University, Québec City, QC G1V 0A6, Canada.
  • Ho CK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Kreuzer J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Foo TK; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
  • Hardy EJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Dellaire G; Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Haas W; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
  • Xia B; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
  • Masson JY; CHU de Québec Research Center, Oncology Axis, Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Laval University, Québec City, QC G1V 0A6, Canada. Electronic address: jean-yves.masson@crchudequebec.ulaval.ca.
  • Zou L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: zou.lee@mgh.harvard.edu.
Mol Cell ; 65(2): 336-346, 2017 Jan 19.
Article en En | MEDLINE | ID: mdl-28089683
ABSTRACT
ATR is a key regulator of cell-cycle checkpoints and homologous recombination (HR). Paradoxically, ATR inhibits CDKs during checkpoint responses, but CDK activity is required for efficient HR. Here, we show that ATR promotes HR after CDK-driven DNA end resection. ATR stimulates the BRCA1-PALB2 interaction after DNA damage and promotes PALB2 localization to DNA damage sites. ATR enhances BRCA1-PALB2 binding at least in part by inhibiting CDKs. The optimal interaction of BRCA1 and PALB2 requires phosphorylation of PALB2 at S59, an ATR site, and hypo-phosphorylation of S64, a CDK site. The PALB2-S59A/S64E mutant is defective for localization to DNA damage sites and HR, whereas the PALB2-S59E/S64A mutant partially bypasses ATR for its localization. Thus, HR is a biphasic process requiring both high-CDK and low-CDK periods. As exemplified by the regulation of PALB2 by ATR, ATR promotes HR by orchestrating a "CDK-to-ATR switch" post-resection, directly coupling the checkpoint to HR.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Roturas del ADN de Doble Cadena / Reparación del ADN por Recombinación Límite: Humans Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Roturas del ADN de Doble Cadena / Reparación del ADN por Recombinación Límite: Humans Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos